1. Home
  2. BXSL vs BIO Comparison

BXSL vs BIO Comparison

Compare BXSL & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BXSL
  • BIO
  • Stock Information
  • Founded
  • BXSL 2018
  • BIO 1952
  • Country
  • BXSL United States
  • BIO United States
  • Employees
  • BXSL N/A
  • BIO N/A
  • Industry
  • BXSL Trusts Except Educational Religious and Charitable
  • BIO Biotechnology: Laboratory Analytical Instruments
  • Sector
  • BXSL Finance
  • BIO Industrials
  • Exchange
  • BXSL Nasdaq
  • BIO Nasdaq
  • Market Cap
  • BXSL 7.5B
  • BIO 6.2B
  • IPO Year
  • BXSL N/A
  • BIO N/A
  • Fundamental
  • Price
  • BXSL $31.90
  • BIO $226.40
  • Analyst Decision
  • BXSL Buy
  • BIO Strong Buy
  • Analyst Count
  • BXSL 6
  • BIO 4
  • Target Price
  • BXSL $31.38
  • BIO $330.50
  • AVG Volume (30 Days)
  • BXSL 855.9K
  • BIO 374.2K
  • Earning Date
  • BXSL 05-07-2025
  • BIO 07-31-2025
  • Dividend Yield
  • BXSL 9.66%
  • BIO N/A
  • EPS Growth
  • BXSL N/A
  • BIO N/A
  • EPS
  • BXSL 3.14
  • BIO N/A
  • Revenue
  • BXSL $1,380,706,000.00
  • BIO $2,541,100,000.00
  • Revenue This Year
  • BXSL $9.80
  • BIO N/A
  • Revenue Next Year
  • BXSL $6.52
  • BIO $3.69
  • P/E Ratio
  • BXSL $10.16
  • BIO N/A
  • Revenue Growth
  • BXSL 16.76
  • BIO N/A
  • 52 Week Low
  • BXSL $25.89
  • BIO $215.38
  • 52 Week High
  • BXSL $34.64
  • BIO $387.99
  • Technical
  • Relative Strength Index (RSI)
  • BXSL 62.21
  • BIO 41.49
  • Support Level
  • BXSL $30.78
  • BIO $220.31
  • Resistance Level
  • BXSL $32.21
  • BIO $233.28
  • Average True Range (ATR)
  • BXSL 0.51
  • BIO 8.26
  • MACD
  • BXSL 0.11
  • BIO -1.40
  • Stochastic Oscillator
  • BXSL 82.79
  • BIO 16.29

About BXSL Blackstone Secured Lending Fund of Beneficial Interest

Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities.

About BIO Bio-Rad Laboratories Inc.

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Share on Social Networks: